HalozymeHALO
HALO
About: Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Employees: 350
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
189% more call options, than puts
Call options by funds: $26M | Put options by funds: $8.99M
125% more funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 9 (+5) [Q1 2025]
90% more first-time investments, than exits
New positions opened: 93 | Existing positions closed: 49
33% more repeat investments, than reductions
Existing positions increased: 215 | Existing positions reduced: 162
31% more capital invested
Capital invested by funds: $5.86B [Q4 2024] → $7.68B (+$1.82B) [Q1 2025]
7% more funds holding
Funds holding: 500 [Q4 2024] → 535 (+35) [Q1 2025]
1.12% more ownership
Funds ownership: 96.27% [Q4 2024] → 97.39% (+1.12%) [Q1 2025]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$47
18%
downside
Avg. target
$61
6%
upside
High target
$72
26%
upside
5 analyst ratings
1 positive
20%
3 neutral
60%
1 negative
20%
HC Wainwright & Co. Mitchell Kapoor | 26%upside $72 | Buy Reiterated | 29 May 2025 |
Morgan Stanley Vikram Purohit | 8%upside $62 | Equal-Weight Downgraded | 14 May 2025 |
Leerink Partners | 18%downside $47 | Underperform Downgraded | 13 May 2025 |
Wells Fargo Mohit Bansal | 14%upside $65 | Equal-Weight Maintained | 7 May 2025 |
JP Morgan Jessica Fye | 1%upside $58 | Neutral Maintained | 21 Apr 2025 |
Financial journalist opinion
Based on 6 articles about HALO published over the past 30 days
Positive
Zacks Investment Research
1 week ago
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Neutral
PRNewsWire
1 week ago
Halozyme Therapeutics Added to Russell 1000® Index
SAN DIEGO , June 30, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that it has been added to the U.S. large-cap Russell 1000® Index, effective after market close on June 27 th, as part of the 2025 FTSE Russell indexes annual reconstitution. The Russell 1000® Index includes approximately 1,000 of the largest U.S. securities based on market capitalization and is widely used by investors as a benchmark for the performance of large-cap stocks.
Positive
Zacks Investment Research
1 week ago
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Neutral
PRNewsWire
3 weeks ago
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO , June 20, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) developed with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme (rHuPH20), for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins. VYVGART is the first and only targeted IgG Fc-antibody fragment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and the first novel mechanism of action for CIDP treatment in more than 30 years.
Positive
Zacks Investment Research
3 weeks ago
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Positive
Zacks Investment Research
4 weeks ago
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Negative
Zacks Investment Research
1 month ago
Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
Positive
Zacks Investment Research
1 month ago
4 Stocks With Strong Interest Coverage Ratios to Buy in June 2025
STRL, BJ, MOH, and HALO shine with strong interest coverage ratios, signaling solid fundamentals for June 2025.
Neutral
PRNewsWire
1 month ago
Halozyme to Participate at Upcoming Investor Conferences
SAN DIEGO , May 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to participate and host investor meetings at the following investor conferences. Details on the Company's participation are as follows: Event: Benchmark 2025 Healthcare House Call Virtual Conference Format: 1x1 Meetings Date: Thursday, May 29, 2025 Event: Goldman Sachs 46th Annual Global Healthcare Conference 2025 Format: Fireside Chat and 1x1 Meetings Date: Monday, June 9, 2025 Presentation Time: 7:00am PT / 10:00am ET A live audio webcast of the presentation will be available in the Investor Relations section of the Company's website.
Positive
Zacks Investment Research
1 month ago
3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
Charts implemented using Lightweight Charts™